A 52-year-old man with a BMI of 31 kg/m² is found to have fasting blood glucose 145 mg/dL and HbA1c 7.8% on routine screening. He is asymptomatic. Serum C-peptide is elevated at 3.2 ng/mL (normal 0.8–3.1), and autoimmune markers (anti-GAD, anti-IA2) are negative. What is the most common cause of diabetes mellitus in this patient?

Explanation

## Diagnosis: Type 2 Diabetes Mellitus ### Clinical Presentation The patient presents with asymptomatic hyperglycemia discovered on screening in a middle-aged, overweight individual—the classic presentation of Type 2 DM. ### Diagnostic Clues - **Elevated C-peptide**: indicates ongoing beta-cell function and endogenous insulin production - **Negative autoimmune markers**: rules out autoimmune beta-cell destruction - **Older age at presentation**: Type 2 DM typically manifests after age 40 - **Overweight/obesity (BMI 31)**: strong risk factor for Type 2 DM - **Asymptomatic discovery**: Type 2 DM often identified incidentally; acute symptoms are absent ### Pathophysiology of Type 2 DM **Key Point:** Type 2 diabetes is characterized by **insulin resistance** (impaired cellular response to insulin) combined with **progressive beta-cell dysfunction** (declining insulin secretion over time). #### Two-Hit Model of Type 2 DM ```mermaid flowchart TD A[Genetic predisposition + Environmental factors]:::outcome --> B[Insulin Resistance]:::outcome B --> C{Compensatory beta-cell response?}:::decision C -->|Adequate: Beta-cells increase insulin output| D[Impaired fasting glucose/IGT]:::outcome C -->|Inadequate: Beta-cell dysfunction develops| E[Type 2 DM]:::outcome B --> F[Increased hepatic glucose output] B --> G[Decreased peripheral glucose uptake] F --> H[Hyperglycemia]:::outcome G --> H E --> I[Progressive beta-cell failure over years]:::outcome ``` #### Mechanisms of Insulin Resistance 1. **Genetic factors**: Polymorphisms in genes regulating glucose metabolism (PPARG, TCF7L2) 2. **Obesity**: Adipose tissue produces inflammatory cytokines (TNF-α, IL-6) and adipokines (decreased adiponectin) → impaired insulin signaling 3. **Lipotoxicity**: Elevated free fatty acids → ectopic fat deposition in muscle and liver → insulin receptor substrate dysfunction 4. **Mitochondrial dysfunction**: Reduced oxidative capacity in skeletal muscle 5. **Chronic inflammation**: Low-grade systemic inflammation impairs insulin signaling #### Progressive Beta-Cell Dysfunction - **Initial phase**: Beta-cells compensate by increasing insulin secretion (hyperinsulinemia) - **Intermediate phase**: Impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) develops - **Late phase**: Beta-cell exhaustion → declining insulin secretion → overt hyperglycemia - **Timeline**: Typically 10–15 years from insulin resistance to Type 2 DM diagnosis ### Type 2 DM vs. Type 1 DM | Feature | Type 2 DM | Type 1 DM | |---------|-----------|----------| | **Pathophysiology** | Insulin resistance + beta-cell dysfunction | Autoimmune beta-cell destruction | | **C-peptide** | Normal or elevated (early); reduced (late) | Low/undetectable | | **Autoimmune markers** | Negative | Positive (GAD, IA2, ZnT8) | | **Onset** | Insidious (months to years) | Acute (days to weeks) | | **Age of onset** | Usually >40 years | Usually <30 years | | **BMI** | Often >25 kg/m² | Normal or low | | **Insulin requirement** | Not required initially; may need later | Required from diagnosis | | **Prevalence** | 85–90% of all diabetes | 10–15% of all diabetes | **High-Yield:** In Type 2 DM, **elevated or normal C-peptide at diagnosis** indicates preserved beta-cell function and distinguishes it from Type 1 DM (where C-peptide is undetectable). **Clinical Pearl:** The natural history of Type 2 DM involves progressive loss of beta-cell function at a rate of ~3–4% per year. Many patients eventually require insulin therapy despite initially being managed with oral agents. **Mnemonic: IRIS** — **I**nsulin **R**esistance, **I**ncreasing insulin output, **S**econdary beta-cell failure.